Nothing Special   »   [go: up one dir, main page]

IN2012DN05192A - - Google Patents

Download PDF

Info

Publication number
IN2012DN05192A
IN2012DN05192A IN5192DEN2012A IN2012DN05192A IN 2012DN05192 A IN2012DN05192 A IN 2012DN05192A IN 5192DEN2012 A IN5192DEN2012 A IN 5192DEN2012A IN 2012DN05192 A IN2012DN05192 A IN 2012DN05192A
Authority
IN
India
Prior art keywords
diseases
aqueous solution
liquid composition
compound
formula
Prior art date
Application number
Other languages
English (en)
Inventor
Styrbjorn Bystrom
Charlotta Liljebris
Ninus Caram-Lelham
Original Assignee
Aprea Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aprea Ab filed Critical Aprea Ab
Publication of IN2012DN05192A publication Critical patent/IN2012DN05192A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN5192DEN2012 2010-01-21 2011-01-21 IN2012DN05192A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29696410P 2010-01-21 2010-01-21
EP10151326 2010-01-21
PCT/EP2011/050854 WO2011089234A2 (en) 2010-01-21 2011-01-21 Method and composition

Publications (1)

Publication Number Publication Date
IN2012DN05192A true IN2012DN05192A (es) 2015-10-23

Family

ID=42212171

Family Applications (1)

Application Number Title Priority Date Filing Date
IN5192DEN2012 IN2012DN05192A (es) 2010-01-21 2011-01-21

Country Status (21)

Country Link
US (1) US9061016B2 (es)
EP (1) EP2525796B1 (es)
JP (2) JP5845193B2 (es)
KR (1) KR101727085B1 (es)
CN (2) CN106963759B (es)
AU (1) AU2011208681B2 (es)
BR (1) BR112012017994B8 (es)
CA (1) CA2786824C (es)
CY (1) CY1117659T1 (es)
DK (1) DK2525796T3 (es)
ES (1) ES2578513T3 (es)
HU (1) HUE028285T2 (es)
IL (1) IL220318A (es)
IN (1) IN2012DN05192A (es)
PL (1) PL2525796T3 (es)
PT (1) PT2525796T (es)
RU (1) RU2571566C2 (es)
SG (1) SG182537A1 (es)
SM (1) SMT201600189B (es)
WO (1) WO2011089234A2 (es)
ZA (1) ZA201204424B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE028285T2 (en) * 2010-01-21 2016-12-28 Aprea Ab An aqueous solution containing 3-quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease
CN104860994A (zh) * 2014-02-20 2015-08-26 中国药科大学 3-奎宁环酮类含磷化合物的制备及其医药用途
CN109280056A (zh) * 2017-07-21 2019-01-29 上海时莱生物技术有限公司 手性3-奎宁环酮类化合物、制备方法及用途
EP3762035A4 (en) * 2018-03-09 2022-03-02 Texas Tech University System COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF CANCER IN ALT
US20220087987A1 (en) * 2018-12-27 2022-03-24 National Cancer Center A method for treating swi/snf complex-deficient cancers comprising glutathione (gsh) metabolic pathway inhibitor
US20220339141A1 (en) 2019-09-18 2022-10-27 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein
EP4100407A1 (en) * 2020-02-09 2022-12-14 Newave Pharmaceutical Inc. Quinuclidinone analogues as anticancer agents
CN111257458B (zh) * 2020-02-20 2022-07-22 北京鑫开元医药科技有限公司海南分公司 一种3-奎宁环酮盐酸盐的检测方法及应用
WO2021170772A1 (en) 2020-02-26 2021-09-02 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of cd47 mediated signaling
WO2021180338A1 (en) 2020-03-09 2021-09-16 Aprea Therapeutics Ab Combination treatment with a p53 reactivator and an inhibitor of dna methyltransferase post stem cell transplant

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3775418A (en) * 1970-07-15 1973-11-27 American Home Prod 3-((3-azaspiro(5,5)undecino)methyl)-3-quinuclidinol
ES2316473T3 (es) 2000-09-20 2009-04-16 Aprea Ab Uso de derivados de 1-azabiciclo(2.2.2)octan-3-ona para el tratamiento de tumores.
US6667344B2 (en) 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
RU2226288C2 (ru) 2001-07-10 2004-03-27 ОПТИВА, Инк. Многослойное оптическое покрытие
ATE333280T1 (de) * 2002-02-21 2006-08-15 Aprea Ab Verwendung von niedermolekularen verbindungen zur herstellung eines medikaments zur behandlung von durch mutation p53-vermittelten erkrankungen
WO2004084893A1 (en) 2003-03-24 2004-10-07 Aprea Ab Pharmaceutical use of 1-azabicyclo[2.2.2]octanes and a method of testing compounds for the ability of activating inactive wt p53
SE0400708D0 (sv) * 2004-03-22 2004-03-22 Aprea Ab New compounds and use thereof
JP2007269786A (ja) * 2006-03-09 2007-10-18 Daiichi Sankyo Healthcare Co Ltd パンテチン含有経口液剤
JP2008001606A (ja) * 2006-06-20 2008-01-10 Mitsubishi Pharma Corp ピラゾロン化合物を含有する水溶液剤
RU2419421C2 (ru) 2006-07-18 2011-05-27 Хенфарма Лабораторио С.Л. Инъецируемая жидкая композиция парацетамола
JP2008201778A (ja) 2007-01-25 2008-09-04 Mochida Pharmaceut Co Ltd バンコマイシン液状製剤
PT2131845E (pt) * 2007-03-01 2012-07-10 Novartis Ag Sais de adição de ácido, hidratos e polimorfos da etilamida do ácido 5-(2,4-di-hidroxi-5-isopropil-fenil)-4- (4-morfolin-4-ilmetil-fenil)-isoxazole-3-carboxílico e formulações compreendendo estas formas
HUE028285T2 (en) * 2010-01-21 2016-12-28 Aprea Ab An aqueous solution containing 3-quinuclidinones for the treatment of hyperproliferative, autoimmune and heart disease

Also Published As

Publication number Publication date
CN106963759A (zh) 2017-07-21
RU2012135698A (ru) 2014-02-27
RU2571566C2 (ru) 2015-12-20
AU2011208681A1 (en) 2012-07-05
CY1117659T1 (el) 2017-05-17
BR112012017994B1 (pt) 2020-01-14
EP2525796B1 (en) 2016-03-30
CN106963759B (zh) 2020-07-07
ZA201204424B (en) 2013-08-28
AU2011208681B2 (en) 2014-10-23
KR101727085B1 (ko) 2017-04-14
PL2525796T3 (pl) 2016-09-30
JP2016020356A (ja) 2016-02-04
PT2525796T (pt) 2016-07-11
CN102781447B (zh) 2016-11-23
HUE028285T2 (en) 2016-12-28
KR20120123441A (ko) 2012-11-08
ES2578513T3 (es) 2016-07-27
SMT201600189B (it) 2016-08-31
SG182537A1 (en) 2012-08-30
US9061016B2 (en) 2015-06-23
JP2013518036A (ja) 2013-05-20
BR112012017994A2 (pt) 2016-05-03
JP6106228B2 (ja) 2017-03-29
WO2011089234A3 (en) 2011-10-06
CA2786824C (en) 2018-04-10
BR112012017994B8 (pt) 2020-12-08
US20120289503A1 (en) 2012-11-15
CA2786824A1 (en) 2011-07-28
CN102781447A (zh) 2012-11-14
IL220318A (en) 2015-10-29
WO2011089234A2 (en) 2011-07-28
JP5845193B2 (ja) 2016-01-20
DK2525796T3 (en) 2016-07-04
WO2011089234A8 (en) 2012-09-07
EP2525796A2 (en) 2012-11-28
AU2011208681A8 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
IN2012DN05192A (es)
PH12016500225A1 (en) Novel quinoline-substituted compound
PH12015500561A1 (en) Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using same
IN2012DN00692A (es)
MX2012001618A (es) Derivados de 5-fluoropirimidinona.
MX2012012530A (es) Derivados de n1-sulfonil-5-fluorpirimidinona.
PH12015501576A1 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
NZ626618A (en) Hydroxamic acid derivatives and uses thereof
EA201201648A1 (ru) Стимуляторы sgc
NZ609309A (en) Redox drug derivatives
MX2013004004A (es) Pirrolidinonas como inhibidores de metionina aminopeptidasa (metap-2).
MX337549B (es) Derivados de insulina que contienen enlaces disulfuro adicionales.
MD4112C1 (ro) Compuşi coordinativi ai cuprului cu 4-(dimetilfenil)-tiosemicarbazonele 2-formilpiridinei
MX342947B (es) Tratamiento de diabetes tipo 2.
GEP20196969B (en) New therapeutical composition containing apomorphine as active ingredient
IN2012DN00695A (es)
MX2012001620A (es) Derivados de n1-acil-5-fluoropirimidinona.
JO3063B1 (ar) مركب مبتكر وطرق لانتاجه
MX2009007265A (es) Sales, composiciones liquidas acuosas que cotienen sales de acido s-(+)-abscisico y metodos para su preparacion.
MX2013002208A (es) Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.
MX336369B (es) Uso de acido elagico como agentes anticaspa.
GEP20156399B (en) Microbiocidal heterocycles
MX354846B (es) Metodos para tratar gota en sub-poblaciones de pacientes.
TW201129357A (en) Novel compound, antitumor agent, and medicines, food or cosmetics with antitumor action
MX2013011561A (es) Compuestos de benzodioxepina y benzodioxina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes.